Vanderbilt Researchers Discover First Selective TAOK1 Inhibitor and Unexpected pan-TAOK Activator, Opening New Avenues for Alzheimer's Research
核心洞察
Vanderbilt scientists developed VU6083859 (搜索), the first selective inhibitor of TAOK1 (搜索), a protein linked to Alzheimer's disease (搜索) that has remained poorly understood due to a lack of suitable research tools.
The same research unexpectedly yielded VU6080195 (搜索), a compound that activates all three TAOK family proteins rather than inhibiting them, offering a novel direction for studying neurological effects.
Both tool compounds emerged from the Warren Center for Neuroscience Drug Discovery, a clinical-stage biotech startup within Vanderbilt with five compounds currently in phase I clinical trials.
Alzheimer's disease (搜索) affects more than seven million people in the United States and remains the leading cause of dementia, yet the scientific community has struggled to develop curative or preventative treatments. Now, researchers at the Vanderbilt University Warren Center for Neuroscience Drug Discovery (搜索) (WCNDD) have created two new tool compounds that could illuminate the hidden biology of a poorly understood protein family linked to the disease.
"Alzheimer's is a condition that remains recalcitrant to the scientific community's attempts at developing a cure or preventative treatment," said Daniel Schultz, a former postdoctoral fellow at the WCNDD and co-first author of the study.
A Persistent Gap in Disease Biology
A major obstacle to developing better therapies for Alzheimer's — and many other neurological diseases and neurodevelopmental disorders — is that researchers still do not fully grasp the underlying biology. Scientists have identified genes and proteins that may contribute to these conditions, but studying them has been extremely difficult without reliable ways to modulate how those biological targets behave.
Tool compounds offer a solution. These chemicals interact with specific proteins and either raise or reduce their activity. While many tool compounds are unsuitable as medicines due to off-target effects or toxicity, they remain invaluable for investigating protein function — knowledge that can become an important early step toward developing new treatments.
Zeroing In on TAOK1 (搜索)
In a study published in ACS Chemical Neuroscience, Schultz and co-first author Lauren Parr, a Ph.D. student in the Department of Pharmacology, developed a compound that selectively inhibits TAOK1 (搜索). The protein has been connected to Alzheimer's disease (搜索) but has remained understudied, partly because researchers lacked suitable compounds for probing its function.
Most of the work was carried out at the WCNDD under the leadership of Executive Director Craig Lindsley. The WCNDD operates as a clinical-stage biotech startup within Vanderbilt, with a drug discovery pipeline that currently includes five compounds in phase I clinical trials. The center is also a founding pillar of the new Vanderbilt Institute for Therapeutic Advances, a next-generation drug discovery institute also led by Lindsley.
To identify useful compounds, Schultz, Parr, and the WCNDD research team created a large collection of related molecules, each with slightly different structures. They then evaluated how the compounds affected TAOK1 (搜索) and assessed whether they possessed properties considered desirable in potential drugs.
"This project showcased the strength of the WCNDD's drug discovery infrastructure," Schultz said.
The First Selective TAOK1 (搜索) Inhibitor
The coordinated effort led to the discovery of VU6083859 (搜索), the first selective inhibitor of TAOK1 (搜索). The compound could provide a starting point for research aimed at developing future Alzheimer's disease (搜索) treatments.
An Unexpected Activator Emerges
Another molecule produced a surprising result. The compound, named VU6080195 (搜索), activated all three proteins in the TAOK family rather than inhibiting them.
"Our understanding of TAOK proteins largely centers around their inhibition, so we are excited at the prospect of studying the neurological effects of increasing their activity," Schultz said. "As scientists, we can get lost in planning our projects to the last detail and expecting things to go a certain way, so it was quite fun to see this unexpected result."
Spurring Future Investigation
Schultz expressed hope that the two compounds will encourage more researchers to investigate the TAOK protein family, which has received relatively little attention in in vivo models to date. A deeper understanding of disease biology can improve the chances of finding effective treatments. With these two tool compounds now available, neuroscientists can examine how the TAOK protein family functions and explore its links to Alzheimer's and other neurological diseases.
The findings could eventually help researchers identify new treatment strategies and perhaps contribute to the long-term search for a cure.
The research was funded by the William K. Warren Foundation and received support from the Zenobia and Mark Godschalk Alzheimer's Research Endowment, the Helen H. and Morris D. Hartman, MD 1910, Neurological Research Fund, the Warren Center for Neuroscience Drug Discovery, and the Vanderbilt Institute for Therapeutic Advances.